Key result
Neither diabetes (adjusted IRR 1.12) nor the TBC1D4 variant significantly increased the risk of incident cardiovascular disease among Inuit in Greenland over a median 10-year follow-up.
Why the study?
Cardiovascular disease is a known complication of diabetes, but its association and the impact of the common diabetogenic TBC1D4 variant had not been studied among Inuit in Greenland.
Does diabetes or the common diabetogenic TBC1D4 p.Arg684Ter variant increase the risk of incident cardiovascular disease among Inuit in Greenland?
Cohort (n=4,127)
Does diabetes or the common diabetogenic TBC1D4 p.Arg684Ter variant increase the risk of incident cardiovascular disease among Inuit in Greenland?
Relative Risk: 1.12 (95% CI 0.8–1.57)
Absolute Event Rate: 18.8% vs 9%
p-value: p=0.50
Neither diabetes nor the common diabetogenic TBC1D4 variant significantly increased the risk of incident cardiovascular disease among Inuit in Greenland, challenging traditional risk associations in this specific population.
Cardiovascular disease (CVD) is a well-known complication of diabetes, but the association has not been studied among Inuit in Greenland. The aim was to examine the association between diabetes and incident CVD among Inuit in Greenland and determine if the common diabetogenic TBC1D4 variant confers increased risk of CVD. We followed an initial study population of 4127 adults in Greenland who had participated in at least one population-based health survey, in national registers. We used Poisson regression to calculate incidence rate ratios (IRR) of cardiovascular endpoints, comparing participants with and without diabetes and comparing homozygous TBC1D4 carriers with heterozygous carriers and non-carriers combined. Close to 10% had diabetes and age range was 18-96 years (45% male). Of the 3924 participants without prior CVD, 362 (~ 9%) had CVD events during a median follow-up of 10 years. Multivariate IRR for the effect of diabetes on CVD was 1.12 (95% CI: 0.80, 1.57) p = 0.50. Using a recessive genetic model, we compared homozygous TBC1D4 carriers with wildtype and heterozygous carriers combined, with a multivariate IRR of 1.20 (95% CI: 0.69, 2.11) p = 0.52. Neither diabetes nor the TBC1D4 variant significantly increased CVD risk among Inuit in Greenland in adjusted models.
No takes yet. Share an insight, caveat, or question.
Overvad et al. (2020) conducted a cohort in Diabetes and TBC1D4 p.Arg684Ter variant (n=4,127). Diabetes vs. Normoglycemia was evaluated on Incident cardiovascular disease (CVD) events (IRR 1.12, 95% CI 0.80-1.57, p=0.50). Neither diabetes (adjusted IRR 1.12) nor the TBC1D4 variant significantly increased the risk of incident cardiovascular disease among Inuit in Greenland over a median 10-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: